gene knockdown

ARF4 siRNA (Human)

MBS8200298

15 nmol

365 USD

siRNA

ARF4 siRNA (Human)

[ARF4]

[ARF2; ADP-ribosylation factor 4]

[ADP-ribosylation factor 4; ADP-ribosylation factor 4; ADP-ribosylation factor 4; ADP-ribosylation factor 4]

[ARF4]

[ARF4; ARF4; ARF2; ARF2]

ARF4_HUMAN

Human

180

ARF4 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.

> 97%

Lyophilized powder

Shipped at 4 degree C. Store at -20 degree C for one year.

RNA Interference (RNAi)

Source: Synthetic. Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency. Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well). Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human ARF4 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.

siRNA to inhibit ARF4 expression using RNA interference

4502205

NP_001651.1

NM_001660.3

P18085

20,511 Da

Assembly Of The Primary Cilium Pathway (1268846); Cargo Trafficking To The Periciliary Membrane Pathway (1268848); EGFR1 Signaling Pathway (198782); ErbB1 Downstream Signaling Pathway (138057); Organelle Biogenesis And Maintenance Pathway (1268838); VxPx Cargo-targeting To Cilium Pathway (1268849)

This gene is a member of the human ARF gene family whose members encode small guanine nucleotide-binding proteins that stimulate the ADP-ribosyltransferase activity of cholera toxin and play a role in vesicular trafficking and as activators of phospholipase D. The gene products include 5 ARF proteins and 11 ARF-like proteins and constitute one family of the RAS superfamily. The ARF proteins are categorized as class I, class II and class III; this gene is a class II member. The members of each class share a common gene organization. The ARF4 gene spans approximately 12kb and contains six exons and five introns. This gene is the most divergent member of the human ARFs. Conflicting map positions at 3p14 or 3p21 have been reported for this gene. [provided by RefSeq, Jul 2008]

ARF4: GTP-binding protein that functions as an allosteric activator of the cholera toxin catalytic subunit, an ADP- ribosyltransferase. Involved in protein trafficking; may modulate vesicle budding and uncoating within the Golgi apparatus. Belongs to the small GTPase superfamily. Arf family. Protein type: G protein, monomeric, ARF; G protein; Motility/polarity/chemotaxis; G protein, monomeric. Chromosomal Location of Human Ortholog: 3p14.3. Cellular Component: Golgi apparatus; membrane; cytosol. Molecular Function: GTPase activity; protein binding; GTP binding; epidermal growth factor receptor binding. Biological Process: vesicle-mediated transport; epidermal growth factor receptor signaling pathway; phospholipase D activation; cell migration; protein transport; protein amino acid ADP-ribosylation; small GTPase mediated signal transduction; organelle organization and biogenesis; positive regulation of transcription from RNA polymerase II promoter; response to axon injury; brain development; negative regulation of apoptosis

15 nmol

365 USD

30 nmol

515